Patient profiles in psoriatic disease: a case-based approach.
Psoriasis and psoriatic arthritis are related conditions that can have numerous untoward consequences. Moreover, appropriate management of these conditions can be challenging, as each affected patient has unique needs that must be addressed. With that in mind, the authors discuss three real-life cases, highlighting principles that may facilitate the effective case-by-case management of psoriatic disease.
Wiatrowski
Mary
M
Texas Dermatology Associates' Specialty Psoriasis Clinic, Dallas, TX, USA.
Furfaro
Nicole
N
D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000077944:Alefacept; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; D000068879:Adalimumab; D000068800:Etanercept; C472181:efalizumab